Look up one drug

Ontario coverage, price, criteria word for word, Health Canada status and shortages for one product

Patient plan: look up a medication list

MUPIROCIN

All products: not a benefit

Other products in the same Health Canada class (D06AX) — coverage varies; not interchangeable

  • Fusidic acid (Fucidin): general benefit
  • Mupirocin (Stramucin): general benefit
  • Fusidate (Fucidin): general benefit

Bactroban · DIN 01916947 · 2% · Oint

Listed, not a benefit; Health Canada lists this DIN as Cancelled post market since 2020-07-24 — choose a marketed DIN from the same-category list.Discontinued 2020-07-24 · checked 2026-09-19
StatusListed, not a benefit; Health Canada lists this DIN as Cancelled post market since 2020-07-24 — choose a marketed DIN from the same-category list.
Write on scriptnot a benefit; no Exceptional Access criteria on record; see alternatives; Health Canada lists this DIN as Cancelled post market since 2020-07-24 — choose a marketed DIN from the same-category list.
Patient paysPatient pays: program not supplied; amount cannot be determined.
Private plan unknown: ask. If yes, check its coverage and payer coordination; if no, see the public routes below.
1 brand, same coverage
Bactroban · DIN 01916947 Manufacturer: GlaxoSmithKline Consumer Healthcare Inc.; listing date 1996-10-01 Health Canada: Cancelled post market since 2020-07-24 · brand BACTROBAN · ATC D06AX09 MUPIROCIN · form Ointment · route Topical · ingredients MUPIROCIN 2 % · company Glaxosmithkline consumer healthcare ulc · schedule Non-prescription drugs
Check this DIN again · Health Canada product record

Bactroban: Formulary list price not recorded/unit (unit not stated in source; not the patient's cost)

Formulary data: Ontario extract of Aug 26, 2026 · Health Canada DPD extract of Sep 2, 2026 (Open Government Licence – Canada) · https://health-products.canada.ca/dpd-bdpp/info?lang=eng&code=15207 · Verify on the e-Formulary ↗ (DIN 01916947)

Source record
DIN 01916947: Bactroban Raw flags: notABenefit=Y, sec3=Y Item: 840404008; group id 813; item number 1992; lccId None; manufacturer id GCH Source form: Oint; strength: 2% Recorded listing: Listed, not a benefit; ODB pays only for the benefit products in this interchangeable category Source prices (unrounded): not recorded; ministry not recorded Source: ODB odb-formulary-ed43-extract-2026-08-26.xml extract_date=2026-08-26 DIN=01916947 Health Canada DPD extract of Sep 2, 2026 (Open Government Licence – Canada) · https://health-products.canada.ca/dpd-bdpp/info?lang=eng&code=15207
Interchangeable products
Taro-Mupirocin · DIN 02279983 · $0.5069
Shortage status: not checked (no credentials)
Health Canada lists this DIN as Cancelled post market since 2020-07-24 — choose a marketed DIN from the same-category list.
Other drugs in the same formulary class (84:04:04 Antibiotics) and how they are covered

Matched class: 84:04:04 Antibiotics

Drug-class inventory only. Lists recorded Ontario formulary products, not every Canadian medication; does not recommend treatment. Covered without a code on the Ontario formulary: CLINDAMYCIN PHOSPHATE & BENZOYL PEROXIDE, FUSIDIC ACID, MUPIROCIN CALCIUM, SODIUM FUSIDATE 84:04:04 Antibiotics

FUSIDIC ACID

· 2 products · General benefit · strengths: 2% · Cr

MUPIROCIN CALCIUM

· 1 products · General benefit · strengths: 2% w/w · Cr

SODIUM FUSIDATE

· 2 products · General benefit · strengths: 2% · Oint

CLINDAMYCIN PHOSPHATE & BENZOYL PEROXIDE

· 4 products · General benefit · strengths: 1% & 5% · Gel, Top Gel

CLINDAMYCIN PHOSPHATE & ADAPALENE & BENZOYL PEROXIDE

· 1 products · Limited Use, codes 724 · strengths: 1.2% w/w & 0.15% w/w & 3.1% w/w · Top Gel Pump

CLINDAMYCIN

· 2 products · Off-Formulary Interchangeable, not an ODB benefit · strengths: 1% · Top Sol Source: formulary-ed43-front-matter.txt Part V; ODB odb-formulary-ed43-extract-2026-08-26.xml extract_date=2026-08-26; class 84:04:04
Full class listing Related classes: 84:04:08 Fungicides, 84:04:12 Parasiticides, 84:04:16 Other Anti-Infectives Same formulary class, not same indication: class membership alone does not establish equivalent uses.
What the Health Canada label says it is for
INDICATIONS AND CLINICAL USE Taro-Mupirocin (mupirocin) is considered appropriate for the topical treatment of the following when caused by sensitive strains of staphylococcus and streptococcus species:  impetigo  superficially infected dermatoses  lesions which are moist and weeping For abrasions, minor cuts and wounds, the use of Taro-Mupirocin (mupirocin) may prevent the development of infections by sensitive Gram-positive organisms. To reduce the development of drug-resistant bacteria and maintain the effectiveness of Taro-Mupirocin (mupirocin) and other antibacterial drugs, Taro-Mupirocin (mupirocin) should be used only to treat infections that are proven or strongly suspected to be caused by susceptible bacteria. When culture and susceptibility information are available, they should be considered in selecting or modifying antibacterial therapy. In the absence of such data, local epidemiology and susceptibility patterns may contribute to the empiric selection of therapy. https://pdf.hres.ca/dpd_pm/00047763.PDF PM date: not printed or not captured Source product: TARO-MUPIROCIN; DIN 02279983; fetched 2026-09-10 Product monograph posted by Health Canada; excerpt for lookup only.

Other review policies

For Bactroban: no applicable EAP criteria are held and no ODB benefit is established. These policies do not establish coverage.

For rare, immediately life-, limb- or organ-threatening circumstances, the Compassionate Review Policy may consider an unfunded drug or indication, subject to its criteria and without bypassing the drug review process. Compassionate Review Policy

Compassionate Review Policy: source quote
Where there are rare clinical circumstances in immediately life, limb, or organ-threatening conditions, the Executive Officer will also consider requests for drugs or indications in situations where there has not been a decision by the Executive Officer to provide funding of the drug or indication as part of the Ontario Drug Benefit program (and the EAP), and the drug or indication requested would not circumvent the established review process for new drugs or indications as part of the drug submission process for listing within the Ontario Drug Benefit program. Requests must meet the criteria for the Compassionate Review Policy.

Ontario source; updated September 15, 2026

For cancer drugs, Case-by-Case Review considers rare, immediately life-threatening circumstances when no satisfactory funded treatment exists; its criteria and application process apply. Case-by-Case Review (cancer drugs)

Case-by-Case Review (cancer drugs): source quote
Note: Requests for cancer drugs are considered under the Case-by-Case Review Program (CBCRP) which is administered by Ontario Health (Cancer Care Ontario) on behalf of the Ministry of Health. The CBCRP considers funding requests for drugs (both oral therapies and injectable drugs) for the treatment of cancer in patients who have a rare clinical circumstance that is immediately life-threatening (death is likely within a matter of months) and who require treatment with an unfunded drug, because there is no other satisfactory and funded treatment. Please refer to the Ontario Health website for information on the application process, FAQs, eligibility criteria and program policies.

Ontario source; updated September 15, 2026